[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-reflux\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-reflux":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100463907","phase-4-the-bioavailability-and-effect-on-pouch-ph-of-esomeprazole-after-gastric-bypass-100463907",false,"NCT05320796","The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass","The Bioavailability and Effect on Pouch pH of Esomeprazole as Tablets or in Solution After Laparoscopic Proximal RYGB for Morbid Obesity - an Investigator Blinded Pilot Study","Inclusion Criteria:\n\n* Proximal Roux-en-Y gastric bypass with linear stapled anastomosis 12 months prior to the study investigation\n* Routine administration of proton pump inhibitors for 6 months postoperatively\n* No intake of proton pump inhibitors at least 4 weeks prior to study investigation\n* No marginal ulcers in upper endoscopy prior to placement of wireless BRAVO™ pH monitoring capsule\n* No symptoms related to gastro-esophageal reflux or marginal ulcers (i.e. epigastric pain, retrosternal burning, regurgitation)\n* Informed consent as documented by signature\n\nExclusion Criteria:\n\n* Known intolerance or allergy for Esomeprazol\n* Contraindication for upper endoscopy\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant\n* Women who are pregnant or breast feeding Major hepatic dysfunction","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The objective of this study is to investigate the effect of Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water) on acid production in the gastric pouch by measuring the intragastric pH and the serum concentration of esomeprazole.",[26,27,28],"Obesity","Gastric Reflux","Ulcer, Gastric","RECRUITING","2026-06-08",{"date":32,"type":33},"2026-06-09","ACTUAL",{"date":35,"type":33},"2023-11-01",{"date":37,"type":20},"2027-12-31",{"name":39,"class":40},"Prof Urs Zingg","OTHER"]